NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP)

Historical Holders from Q1 2020 to Q3 2025

Symbol
NBP on Nasdaq
CUSIP
44975P103
Type / Class
Equity / Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares)
Shares outstanding
264M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
29.7M
Holdings value
$112M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
42
Number of buys
31
Number of sells
-16
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Everest Medicines Ltd 16.1% $90.6M 42.5M Everest Medicines Limited Aug 5, 2025
CBC Investment I-Mab Ltd 10.4% -41.7% $58.6M -$12.9M 27.5M -18.1% Wei Fu Aug 5, 2025

Institutional Holders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 29.7M $112M +$77.5M $3.78 42
2025 Q2 9.4M $22.7M +$2.03M $2.42 32
2025 Q1 8.99M $7.41M -$2.24M $0.82 29
2024 Q4 11.9M $10.1M -$4.2M $0.85 27
2024 Q3 14.2M $17.6M -$1.64M $1.24 27
2024 Q2 15.1M $25.3M +$4.92M $1.67 37
2024 Q1 12M $22.4M -$591K $1.86 38
2023 Q4 12.3M $23.5M -$3.93M $1.90 43
2023 Q3 15.3M $20.1M -$8.41M $1.32 47
2023 Q2 18.7M $55.9M -$6.38M $2.99 46
2023 Q1 20.7M $71.6M -$16.5M $3.46 52
2022 Q4 24.9M $104M -$23.8M $4.18 64
2022 Q3 30.8M $123M -$78.5M $4.01 69
2022 Q2 38.2M $430M -$43.1M $11.30 91
2022 Q1 40.3M $654M -$2.81M $16.24 113
2021 Q4 39.1M $1.84B +$49.7M $47.39 128
2021 Q3 36M $2.61B +$445M $72.49 140
2021 Q2 28.3M $2.38B +$495M $83.95 134
2021 Q1 23.3M $1.13B +$491M $48.47 79
2020 Q4 13.1M $615M +$200M $47.15 63
2020 Q3 9.53M $448M +$237M $47.03 48
2020 Q2 3.3M $97.7M -$2.62M $29.93 19
2020 Q1 3.44M $44.7M +$44.7M $13.00 15